Marc Güell
Coordinator of the Translational Synthetic Biology research group and ICREA research professor at Pompeu Fabra University (UPF)
It is urgently necessary to modernize European legislation to bring it in line with current biotechnology. Entirely strategic sectors depend on this, such as food safety and the development of therapies. European legislation, to date, has led to a significant loss of competitiveness in strategic sectors. These directives represent a step forward in addressing this issue regarding genetically modified microorganisms, which play a crucial role in both public health and planetary health challenges.
Under no circumstances should these changes pose greater risks to health or the environment; rather, the opposite is true. Indeed, this legislation should accelerate key technologies for human health, such as microbiome-based therapies; or accelerate solutions for planetary health, such as improved bioremediation solutions [using the metabolic capabilities of living organisms to treat contaminants], reducing dependence on fossil fuels, or producing more sustainable food.